AMENDMENTS TO THE CLAIMS

- 1. **(Withdrawn)** A composite biomaterial for preventing surgical adhesions of tissue comprised of at least one hyaluronic acid derivative selected from the group consisting of:
- (a) a benzyl ester of hyaluronic acid wherein 75 to 100% of the carboxyl groups of hyaluronic acid are esterified with a benzyl radical and up to 25% of the carboxyl groups are esterified with the alkyl radial of a C_{10} to C_{20} aliphatic alcohol, with the proviso that at least 80% of the carboxyl groups are esterified; and
- (b) an auto-crosslinked derivative of hyaluronic acid wherein 0.5 to 20% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.
- 2. **(Withdrawn)** The composite biomaterial according to claim 1, wherein said derivative is the total benzyl ester in which all of the carboxyl groups of hyaluronic acid are esterified with a benzyl group.
- 3. **(Withdrawn)** The composite biomaterial according to claim 1, wherein said derivative is a benzyl ester wherein 80% of the carboxyl groups are esterified with a benzyl group.
- 4. **(Withdrawn)** The composite material according to claim 1, wherein said derivative is a benzyl ester wherein 75% of the carboxyl groups are esterified with a benzyl group and the

Application No. 10/812,587 Amendment dated February 28, 2007 Reply to Office Action of September 29, 2006

remaining 25% carboxyl groups are esterified with the aliphatic residue of a C_{10-20} aliphatic alcohol.

- 5. **(Withdrawn)** The composite material according to claim 4, wherein said alcohol is stearyl or palmitic alcohol.
- 6. **(Withdrawn)** The composite material according to claim 1, wherein said autocrosslinked derivative has 4.5 to 5.0% of the carboxyl groups of the hyaluronic acid molecule cross-linked.
- 7. **(Withdrawn)** The composite material according to claim 1 which further comprises a non-biodegradable synthetic polymer.
- 8. **(Withdrawn)** The composite material according to claim 7, wherein said synthetic polymer is a member selected from the group consisting of polypropylene, polyethylene, polyester and polytetrafluoroethylene.
- 9. **(Withdrawn)** The composite material according to claim 1 in the form of a membrane, a mesh or a woven or non-woven tissue.

3

10. (Withdrawn) The composite biomaterial according to claim 1 in the form of a gel.

Reply to Office Action of September 29, 2006

11. **(Currently Amended)** A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one hyaluronic acid derivative selected from the group consisting of:

- (a) a benzyl ester of hyaluronic acid wherein 75 to 100% of the carboxyl groups of hyaluronic acid are esterified with a benzyl radical and up to 25% of the carboxyl groups are esterified with the alkyl radical of a C_{10} to C_{20} aliphatic alcohol, with the proviso that at least 80% of the carboxyl groups are esterified; and
- (b) an auto-crosslinked derivative of an hyaluronic acid with an average molecular weight of 150,000 to 730,000 Daltons, wherein 0.54.5 to 205% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule, wherein said cross-linked derivative has a viscosity of at least 200 Pa*sec⁻¹.
- 12. **(Withdrawn)** The method according to claim 11, wherein said derivative is the total benzyl ester in which all of the carboxyl groups of hyaluronic acid are esterified with a benzyl group.
- 13. **(Withdrawn)** The method according to claim 11, wherein said derivative is a benzyl ester wherein 80% of the carboxyl groups are esterified with a benzyl group.

4

Docket No.: 2039-0124PUS2

Reply to Office Action of September 29, 2006

14. **(Withdrawn)** The method according to claim 11, wherein said derivative is a benzyl ester wherein 75% of the carboxyl groups are esterified with a benzyl group and the remaining 25% carboxyl groups are esterified with the aliphatic residue of a C_{10-20} aliphatic alcohol.

- 15. **(Withdrawn)** The method according to claim 14, wherein said alcohol is stearyl or palmitic alcohol.
- 16. (Currently Amended) The method according to claim 11, wherein <u>said viscosity is at least</u>

 250 Pa*sec⁻¹4.5 to 5.0% of the carboxyl groups of said auto-crosslinked derivative has are crosslinked.
- 17. **(Previously Presented)** The method according to claim 11 wherein said biomaterial further comprises a non-biodegradable synthetic polymer.
- 18. **(Previously Presented)** The method according to claim 17, wherein said synthetic polymer is at least one member selected from the group consisting of polypropylene, polyethylene, polyester and polytetrafluoroethylene.
- 19. **(Currently Amended)** The method according to claim 11, wherein said biomaterial is in the form of a gel, a membrane, a mesh or a woven or non-woven tissue.
- 20. (Currently Amended) The biomaterial of method according to Cclaim 11, wherein said biomaterial further comprisesing a biologically active agent.

Docket No.: 2039-0124PUS2

Application No. 10/812,587 Amendment dated February 28, 2007

Reply to Office Action of September 29, 2006

21. **(Currently Amended)** The biomaterial of method of claim 20 wherein the said biologically active agent is selected from the group consisting of steroidal and non-steroidal antiinflammatories, fibrinolytics, hemostatics, antithrombotics, growth factors, antitumorals, antibacterials, antivirals and antifungals.

- 22. **(Withdrawn)** The biomaterial of claim 10 wherein the viscosity of said gel is at least 200 Pa* Sec⁻¹.
- 23. **(Withdrawn)** The biomaterial of claim 10 wherein the viscosity of said gel is at least 300 Pa* Sec⁻¹.
- 24. **(Original)** The method of claim 11 wherein said surgery is selected from the group consisting of abdominal, laparoscopic, laparotomic, intestinal, gynecologic, abdominalpelvic, peritoneal, urogenital, orthopedic, spinal/dura mater, tendon/nerve, including carpal tunnel, cardiovascular, thoracic, ophtalmic, oncologic, plastic, esthetic, ENT, paranasal sinuses, and transplantation.

Docket No.: 2039-0124PUS2